NEW DELHI and MUNICH, June 8, 2023 /PRNewswire/ -- Translumina, a global leader in interventional cardiovascular medical devices with manufacturing presences in Germany and India, today announced the acquisition of Munich-based Lamed GmbH. With this acquisition, Translumina has taken another step toward its stated goal of providing a comprehensive cardiovascular portfolio at scale in key markets globally.
Established in 1989, Lamed is a leading market access platform for cardiovascular and vascular products. It covers more than 1,000 hospitals through its GPO network in Germany, which is the largest interventional cardiology market in Europe; the company exclusively distributes a portfolio of differentiated products for a reference base of international suppliers. Lamed's experienced senior management team brings over 30 years of experience and deep-seated ecosystem relationships. Translumina intends to take advantage of the platform to introduce a number of its own and partner products to the German market.
Lazaros Ayvatoglou, the founder of Lamed, is convinced that he has chosen the right partner in Translumina for the further development of his well-established platform. He said: "After the initial discussion, it became clear that both businesses are mutually enriching with multiple growth opportunities. I am happy to have found a partner who builds on Lamed's established foundation for a successful future."
"This acquisition is strategically important and gives us significant access to the German vascular and cardiovascular markets, one of the largest in Europe. The synergy of our unique technologies and Lamed's market penetration will create a formidable business opportunity for us," said Gurmit Singh Chugh, who together with Punita Sharma founded Translumina in 2010.
Arjun Oberoi, Managing Director of Everstone Capital, said: "Translumina's acquisition of Lamed positions us for accelerated growth in the thriving peripheral vascular and interventional surgery sector in Germany. With access to major GPOs and hospitals in the largest European medical device market, we are poised to excel in the interventional cardiology, peripheral vascular and structural heart disease segments."
Founded in 2010, Translumina is an interventional cardiovascular device company offering world-class products and services. It is a fully integrated product development and manufacturing company with facilities in Germany and India. Over the years, the company has built strategic partnerships with leading hospitals, engineering institutes, global technology companies, and renowned interventional cardiologists. Translumina combines the best of German engineering, intellectual property and high quality standards with the Indian entrepreneurial culture and strong ability to make innovative products at affordable prices.
For more information, visit www.translumina.com
About Everstone Capital
Headquartered in Singapore, Everstone Capital, the venture capital arm of Everstone Group ( everstonegroup.com), is a global firm committed to driving economic growth and sustainable value creation. With seven offices around the world (Singapore, Mumbai, Delhi, Gurgaon, Dubai, New York and Mauritius), Everstone Capital focuses on the middle market with a control mindset and growth bias facilitated by an experienced team comprised of the best investment, operational and strategic resources.
For more information, visit everstonecapital.com
Photo: https://mma.prnewswire.com/media/2094245...Logo: https://mma.prnewswire.com/media/1797972...Logo: https://mma.prnewswire.com/media/ 2094257...
View original content: https://www.prnewswire.com/news-releases/translumina-refuerza-su-presencia-en-alemania-con-la-adquisicion-de-lamed-gmbh-301846146.html